EHA 2024 | The encouraging early results of NX-5948, a novel BTK degrader, in patients with R/R CLL and NHL
Due to their unique mechanism of action, BTK degraders hold the potential to treat patients who become resistant to BTK inhibitor (BTKi) therapy. In this interview, Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, presents the updated results from the ongoing Phase Ia trial (NCT05131022) investigating NX-5948, a novel BTK degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). The agent is well tolerated and elicits durable responses in a heavily pretreated patient population. Dr Linton believes that, in the future, BTK degraders may replace BTKis as the mainstay of treatment in CLL. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
